New auxiliary treatment approved for patients with stage IIIA non-small cell lung cancer approved by Junshi Bio Treplymono
-
Last Update: 2020-06-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Recently, according to relevant news, Junshi bio-Treplymono-approved clinical, for combined chemotherapy in the resectionable phase IIIA non-small cell lung cancer patients of the new auxiliary treatmentAbout Trepri monoantigenTrepri monoantigen is the first domestic PD-1/L1drug(http://approved in China, the first indication approved is melanoma, the product named TuyiJunshi Biological Semi-Annual Report revealed that Trepley mono-anti is currently under going on or will soon carry out a number of clinicaltrials(http://, including second-line nasopharyngeal cancer, second-line urinary disease, first-line nasopharyngeal cancer, first-line EGFR non-mutation (wild type) non-small cells Lung cancer, EGFR-TKI treatment of failed EGFR mutation synty non-small cell lung cancer, hepatocellular carcinoma after surgery assisted therapy, advanced esophageal squamous cancer, first-line melanoma, mucosal melanoma, triynom breast cancer and broad stage small cell lung cancer
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
